ResMed stock holds gains as analysts highlight sleep apnea growth

Published on 09/21/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed stock closed at USD 225.35 on September 18, 2026 on the NYSE, near a market capitalization of about USD 32.2 billion. Analysts recently pointed to high single digit EPS growth over the next three years for the company as of mid September 2026.

RMD, US75102W1036, Illustration mit AI erstellt.

ResMed Inc. (ISIN US75102W1036) stock closed at USD 225.35 on the New York Stock Exchange on September 18, 2026, giving the sleep apnea specialist a market value of roughly USD 32.2 billion according to recent data from finance portals. As MarketBeat reported based on the September 18, 2026 closing price, the shares have been supported by expectations of continued growth in sleep and breathing health and cloud software.

Analysts see EPS growth potential

According to MarketBeat, several analyst notes around September 15, 2026 highlighted that ResMed is projected to achieve high single digit earnings per share growth over the next three years, supported by demand for sleep apnea devices and software connected care.

As MarketBeat relayed from an RBC Capital Markets note dated September 15, 2026, the bank upgraded ResMed following positive fourth quarter developments and pointed to the company’s ability to grow EPS at a high single digit rate annually over the coming three years.

Latest revenue mix and market capitalization

A sector overview from Simply Wall St on September 20, 2026 placed ResMed firmly in the senior and Medicare healthcare theme and estimated that the company generates about USD 5.0 billion in revenue from Sleep and Breathing Health devices and USD 676 million from Residential Care Software, for a combined revenue base of roughly USD 5.7 billion.

The same overview from Simply Wall St indicated a market value near USD 32.2 billion for ResMed, which is consistent with portal snapshots that show a market capitalization of about USD 32.455 billion as of mid September 2026.

Stock level and valuation snapshot

A snapshot on a financial portal that lists ResMed alongside Teleflex showed ResMed at USD 224.99 with a market capitalization of USD 32.455 billion and an industry classification as Medical Instruments and Supplies, as of around September 20, 2026; this price is very close to the USD 225.35 closing level on September 18, 2026, underscoring that the stock has held its recent gains.

ResMed stock price and investor takeaway

ResMed stock thus trades in the mid USD 220s on the NYSE as of the September 18, 2026 closing price, for a market capitalization in the low USD 30 billions and a revenue base around USD 5.7 billion across devices and software. For investors, the combination of projected high single digit EPS growth over the next three years and the company’s established position in sleep apnea and senior healthcare makes valuation and growth expectations the key points to watch around the RMD stock.